SU 5402: Precise Receptor Tyrosine Kinase Inhibitor for FGFR/VEGFR/PDGFR/EGFR Research

Executive Summary: SU 5402 (A3843) is a well-characterized small molecule inhibitor targeting VEGFR2, FGFR1, PDGFRβ, and EGFR, with nanomolar to micromolar potency under cell-based and biochemical conditions (APExBIO). It efficiently blocks FGFR3 phosphorylation and downstream ERK1/2 and STAT3 signaling (Amyloid.co). Preclinical studies show SU 5402 induces cell cycle arrest (G0/G1) and apoptosis in multiple myeloma models with constitutively active FGFR3 (Pelubiprofenchems.com). In vivo, 300 ng/kg reduces ERK1/2 activation in BALB/c mouse tumor models, confirming utility for translational oncology. The compound is supplied as a solid (MW 296.33), insoluble in water/ethanol, but dissolves in DMSO up to ≥14.8 mg/mL for experimental use (APExBIO).

Biological Rationale

Receptor tyrosine kinases (RTKs) regulate critical cell processes, including proliferation, survival, and differentiation. Aberrant activation of FGFR3, VEGFR2, and PDGFRβ is implicated in oncogenesis, particularly in multiple myeloma and solid tumors (Oh et al., 2025). FGFR3 mutations or overexpression drive constitutive downstream signaling through ERK1/2 and STAT3, promoting tumor cell survival and resistance to apoptosis. Pharmacological inhibition of these kinases enables mechanistic dissection of oncogenic pathways and preclinical evaluation of targeted therapies. SU 5402, as a multi-targeted RTK inhibitor, provides a robust tool for delineating the role of FGFR3 and related kinases in cancer and cell signaling research (Amyloid.co). This extends prior work by providing direct biochemical control over multiple relevant kinases.

Mechanism of Action of SU 5402

SU 5402 binds the ATP-binding pocket of target RTKs, competitively inhibiting kinase activity. The compound displays inhibitory concentration (IC₅₀) values of 0.02 μM for VEGFR2, 0.03 μM for FGFR1, 0.51 μM for PDGFRβ, and >100 μM for EGFR (APExBIO). Its primary utility is as an FGFR3 phosphorylation inhibitor, effectively blocking downstream activation of the ERK1/2 and STAT3 signaling pathways. In human myeloma cell lines expressing mutant FGFR3, SU 5402 causes G0/G1 cell cycle arrest and induces apoptosis, as confirmed by flow cytometry and caspase activity assays (Amyloid.co). In vivo, administration at 300 ng/kg in BALB/c mice is sufficient to reduce activated ERK1/2 levels in tumor models (APExBIO).

Evidence & Benchmarks

• SU 5402 inhibits VEGFR2 kinase activity with an IC₅₀ of 0.02 μM under standard in vitro assay conditions (APExBIO, product page).
• FGFR1 activity is suppressed by SU 5402 at 0.03 μM, based on biochemical kinase assays (APExBIO, product page).
• PDGFRβ inhibition is achieved at 0.51 μM; EGFR is only weakly inhibited (>100 μM) (APExBIO, product page).
• SU 5402 blocks FGFR3 phosphorylation and downstream ERK1/2 and STAT3 signaling in human myeloma cell lines expressing constitutively active FGFR3, leading to G0/G1 arrest and apoptosis (Amyloid.co, see here).
• In vivo, 300 ng/kg SU 5402 reduces ERK1/2 activation in BALB/c mouse tumor models, supporting translational relevance (APExBIO, product page).
• Human iPSC-derived neuronal model systems facilitate study of kinase inhibition in neuron-intrinsic mechanisms, extending SU 5402’s application scope (Oh et al., 2025).

For further mechanistic detail and troubleshooting, see the advanced application guide (SU-5416.com), which this article extends by adding recent in vivo benchmarks and updated neuronal model data.

Applications, Limits & Misconceptions

SU 5402 is primarily used in cancer biology, multiple myeloma research, and cell signaling studies involving RTKs. It enables apoptosis assays, cell cycle analysis, and pathway interrogation in both cancer and neuronal systems (Pelubiprofenchems.com). Recent advances incorporate SU 5402 into human iPSC-derived sensory neuron models, revealing novel insights into kinase-dependent regulation of viral latency and reactivation (Oh et al., 2025). This article clarifies and updates the mechanistic insights discussed in FG2216.com by integrating iPSC-neuron findings.

Common Pitfalls or Misconceptions

• SU 5402 is not a pan-RTK inhibitor; it has minimal efficacy against EGFR at concentrations < 100 μM.
• It is not soluble in water or ethanol; improper solvent use can result in precipitation and experimental artifact.
• SU 5402 is for research use only; it is not approved for clinical or diagnostic use in humans.
• Storage at -20°C is required; solution stability is limited, and prolonged storage of solutions results in loss of potency.
• Inhibitory effects may vary by cell type and RTK expression status; always validate in relevant cellular context.

Workflow Integration & Parameters

SU 5402 is supplied as a solid by APExBIO (SKU: A3843) and should be dissolved in DMSO at ≥14.8 mg/mL for use in cell-based and biochemical assays (product page). Typical working concentrations are in the 20 nM - 10 μM range, depending on target kinase sensitivity. For in vivo studies, dosing at 300 ng/kg in BALB/c mice has demonstrated effective ERK pathway inhibition. Storage at -20°C is required for both powder and solutions; solutions should be used promptly. For apoptosis and cell cycle assays, treat cells with SU 5402 for 24-72 hours and assess using flow cytometry and caspase activation assays. For a stepwise protocol and troubleshooting, see "SU 5402: Advanced Receptor Tyrosine Kinase Inhibitor Work..." (SU-5416.com), which this article updates by emphasizing stability and neuronal system applications.

Conclusion & Outlook

SU 5402 remains a gold-standard tool for dissecting RTK signaling in cancer and neuronal contexts. Its selective potency for VEGFR2, FGFR1, and PDGFRβ, with minimal off-target EGFR inhibition, permits targeted interrogation of oncogenic and neurobiological pathways. Emerging models using human iPSC-derived neurons will likely extend SU 5402's impact, enabling refined studies of kinase signaling in development and disease. For further details and product acquisition, see the official APExBIO SU 5402 page.